Menorest

Menorest

A brand name for OESTRADIOL (estradiol).
Mentioned in ?
References in periodicals archive ?
Studd and colleagues compared the efficacy and safety of transdermal estradiol with oral CEE in reducing hot flashes in a randomized, multicenter, double-blind, and double-dummy study (51) (FIGURE 7), In this study, 214 women aged 40 to 65 years with moderate-to-severe hot flashes were administered a continuous regimen of Menorest 50 (transdermal formulation) twice weekly or Premarin (oral CEE) 0.
Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or System (Evorel) 50.
Evorel, Fematrix and Menorest - patches containing oestrogen which lie flat on the skin.
Noven's existing products include advanced estrogen transdermal delivery systems (Vivelle(R) and Vivelle-Dot(TM), licensed to Novogyne, and Menorest, licensed to Rhone-Poulenc Rorer); combination estrogen/progestin transdermal delivery systems (CombiPatch(TM) and Estalis(R), licensed to Rhone-Poulenc Rorer); and the first transmucosal patch delivery system approved by the FDA (DentiPatch(R)).
Noven's existing products include advanced estrogen transdermal delivery systems (Vivelle(R), licensed to Vivelle Ventures LLC, and Menorest, licensed to Rh<W094>ne-Poulenc Rorer); combination estrogen/progestogen transdermal delivery systems (CombiPatch(tm) and Estalis(R), licensed to Rh<W094>ne-Poulenc Rorer); and the first transmucosal patch delivery system approved by the FDA (DentiPatch(R), developed, marketed and sold by Noven).
Noven's existing products include advanced estrogen transdermal delivery systems (Vivelle(R), licensed to Vivelle Ventures LLC, and Menorest, licensed to Rhone-Poulenc Rorer); combination estrogen/progestogen transdermal delivery systems (CombiPatch(TM) and Estalis(R), licensed to Rhone-Poulenc Rorer); and the first transmucosal patch delivery system approved by the FDA (DentiPatch(R), developed, marketed and sold by Noven).
Noven's existing products include leading estrogen transdermal delivery systems (Vivelle(R), licensed to Vivelle Ventures, LLC, and Menorest, licensed to Rhone-Poulenc Rorer); advanced combination of estrogen/progestin transdermal delivery systems (CombiPatchTM and Estalis(R), licensed to Rhone-Poulenc Rorer); and the first transmucosal patch delivery system approved by the FDA (DentiPatch(R), developed, marketed and sold by Noven).
In addition to DentiPatch(R), Noven's existing products include leading estrogen transdermal delivery systems (Vivelle(R), licensed to Vivelle Ventures, LLC, and Menorest, licensed to Rhone-Poulenc Rorer); and advanced combination of estrogen/progestin transdermal delivery systems (CombiPatch(tm) and Estalis(R), licensed to Rhone-Poulenc Rorer).
Noven's existing products include leading estrogen transdermal delivery systems (Vivelle(R), licensed to Vivelle Ventures LLC, and Menorest, licensed to Rhone-Poulenc Rorer); an advanced combination estrogen/progestin transdermal delivery system (CombiPatch(tm) and Estalis(tm), licensed to RPR); and the first transmucosal patch delivery system approved by the FDA (DentiPatch(R), developed, marketed and sold by Noven).
Noven offers innovative products such as Vivelle(r) and Menorest (estrogen transdermal delivery systems), Estalis(tm) (combination estrogen/progestogen transdermal delivery system), and DentiPatch(r) (lidocaine transmucosal delivery system).
Noven offers advanced and innovative products such as Vivelle and Menorest (transdermal estrogen delivery systems), Estalis(tm) (combination estrogen/progestogen transdermal delivery system), and DentiPatch(r) (lidocaine transmucosal delivery system).
Together with its global partners, Noven offers advanced and innovative products such as Vivelle(R) and Menorest (estrogen transdermal delivery systems), Estalis (combination estrogen/progestogen transdermal delivery system), and DentiPatch(R) (lidocaine transoral delivery system).